Bank Of New York Mellon Corp Ideaya Biosciences, Inc. Transaction History

Bank Of New York Mellon Corp

  • $528 Trillion
  • Q2 2024

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 09, 2023
BUY
$13.49 - $18.72 $2.08 Million - $2.88 Million
153,901 New
153,901 $2.11 Billion
Q4 2022

Feb 14, 2023
BUY
$14.47 - $18.17 $2.21 Million - $2.77 Million
152,613 New
152,613 $2.77 Million
Q3 2022

Nov 14, 2022
BUY
$9.24 - $15.79 $115,315 - $197,059
12,480 Added 11.5%
121,009 $1.81 Million
Q2 2022

Aug 15, 2022
SELL
$8.28 - $13.88 $36,241 - $60,752
-4,377 Reduced 3.88%
108,529 $1.5 Million
Q1 2022

May 11, 2022
SELL
$11.18 - $24.02 $17,083 - $36,702
-1,528 Reduced 1.34%
112,906 $1.26 Million
Q4 2021

Feb 11, 2022
BUY
$20.95 - $26.88 $84,051 - $107,842
4,012 Added 3.63%
114,434 $2.71 Million
Q3 2021

Nov 12, 2021
BUY
$17.26 - $27.08 $551,577 - $865,395
31,957 Added 40.73%
110,422 $2.82 Million
Q2 2021

Aug 11, 2021
BUY
$17.76 - $24.83 $529,230 - $739,909
29,799 Added 61.23%
78,465 $1.65 Million
Q1 2021

May 13, 2021
BUY
$13.48 - $23.77 $3,707 - $6,536
275 Added 0.57%
48,666 $1.14 Million
Q4 2020

Feb 09, 2021
BUY
$12.17 - $17.52 $88,049 - $126,757
7,235 Added 17.58%
48,391 $677,000
Q3 2020

Nov 12, 2020
BUY
$11.22 - $14.46 $122,129 - $157,397
10,885 Added 35.96%
41,156 $516,000
Q2 2020

Aug 12, 2020
BUY
$3.59 - $18.57 $108,672 - $562,132
30,271 New
30,271 $430,000

Others Institutions Holding IDYA

# of Institutions
206
Shares Held
73.6M
Call Options Held
21.5K
Put Options Held
20.3K
View Full List

About IDEAYA Biosciences, Inc.

IDYA Quotes by TradingView
  • Ticker IDYA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,067,700
  • Market Cap $1.52B
  • Description
  • IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinica...
More about IDYA
Track This Portfolio

Track Bank Of New York Mellon Corp Portfolio

Follow Bank Of New York Mellon Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

News

Stay updated on Bank Of New York Mellon Corp with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email